Treatment for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Breast Cancer+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.

Eligible Conditions

  • Breast Cancer
  • Breast

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Breast Cancer

Study Objectives

11 Primary · 19 Secondary · Reporting Duration: 3 years

3 years
Cardiovascular risk factors (family history)
Cardiovascular risk factors (hypertension)
Cardiovascular risk factors (tobacco use)
Incidence of diabetes in women with breast cancer versus healthy individuals
Incidence of hyperlipidemia in women with breast cancer versus healthy individuals
Incidence of prediabetes in women with breast cancer versus healthy individuals
Number of breast cancer patients with cardiovascular risk factors (family history)
Number of breast cancer patients with cardiovascular risk factors (hypertension)
Number of breast cancer patients with cardiovascular risk factors (obesity)
Number of breast cancer patients with cardiovascular risk factors (tobacco use)
Number of referrals for individuals with diabetes
Number of referrals for individuals with pre-diabetes
Number of referrals for individuals with risk of cardiovascular disease
Prevalence of diabetes
Prevalence of diabetes in women with breast cancer versus healthy individuals
Prevalence of hyperlipidemia
Prevalence of hyperlipidemia in women with breast cancer versus healthy individuals
Prevalence of prediabetes
Prevalence of prediabetes in women with breast cancer versus healthy individuals
Referrals for individuals with diabetes
Referrals for individuals with pre-diabetes
Referrals for individuals with risk of cardiovascular disease
Month 12
Breast-specific symptoms assessed by the of The European Organisation for Research and Treatment Cancer Quality of Life Questionnaire BR-23
Change in Body Mass Index (BMI)
Change in HbA1c
Change in LDL cholesterol
Change in Quality of Life as assessed by the Quality of Life Questionnaire C30
Change in Quality of Life as assessed by the The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Prevalence of obesity/ overweight
Quality of Life Questionnaire The European Organisation for Research and Treatment Cancer C30

Trial Safety

Safety Progress

1 of 3

Other trials for Breast Cancer

Trial Design

0 Treatment Group

450 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
Closest Location: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, MD
Photo of Baltimore 1Photo of Baltimore 2Photo of Baltimore 3
2011First Recorded Clinical Trial
42 TrialsResearching Breast Cancer
311 CompletedClinical Trials

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
531 Previous Clinical Trials
30,603 Total Patients Enrolled
42 Trials studying Breast Cancer
4,455 Patients Enrolled for Breast Cancer
Jennifer Sheng, M.D.Principal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be able to speak and read English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.